Whittam, D H; Karthikeayan, V; Gibbons, E; Kneen, R; Chandratre, S; Ciccarelli, O; Hacohen, Y; de Seze, J; Deiva, K; Hintzen, R Q; Wildemann, B; Jarius, S; Kleiter, I; Rostasy, K; Huppke, P; Hemmer, B; Paul, F; Aktas, O; Pröbstel, A K; Arrambide, G; Tintore, M; Amato, M P; Nosadini, M; Mancardi, M M; Capobianco, M; Illes, Z; Siva, A; Altintas, A; Akman-Demir, G; Pandit, L; Apiwattankul, M; Hor, J Y; Viswanathan, S; Qiu, W; Kim, H J; Nakashima, I; Fujihara, K; Ramanathan, S; Dale, R C; Boggild, M; Broadley, S; Lana-Peixoto, M A; Sato, D K; Tenembaum, S; Cabre, P; Wingerchuk, D M; Weinshenker, B G; Greenberg, B; Matiello, M; Klawiter, E C; Bennett, J L; Wallach, A I; Kister, I; Banwell, B L; Traboulsee, A; Pohl, D; Palace, J; Leite, M I; Levy, M; Marignier, R; Solomon, T; Lim, M; Huda, S; Jacob, A     «

Whittam, D H; Karthikeayan, V; Gibbons, E; Kneen, R; Chandratre, S; Ciccarelli, O; Hacohen, Y; de Seze, J; Deiva, K; Hintzen, R Q; Wildemann, B; Jarius, S; Kleiter, I; Rostasy, K; Huppke, P; Hemmer, B; Paul, F; Aktas, O; Pröbstel, A K; Arrambide, G; Tintore, M; Amato, M P; Nosadini, M; Mancardi, M M; Capobianco, M; Illes, Z; Siva, A; Altintas, A; Akman-Demir, G; Pandit, L; Apiwattankul, M; Hor, J Y; Viswanathan, S; Qiu, W; Kim, H J; Nakashima, I; Fujihara, K; Ramanathan, S; Dale, R C; Boggild, M...     »

INTRODUCTION: While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus on management is yet to be developed. OBJECTIVE: To survey the current global clinical practice of clinicians treating MOGAD. METHOD: Neurologists worldwide with expertise in treating MOGAD participated in an online survey (February-April 2019). RESULTS: Fifty-two responses were received (response rate 60.5%) from 86 invited experts, comprising adult (78.8%, 41/52) and paediatric (21.2%, 11/52) neurologists in 22 countries. All treat acute attacks with high dose corticosteroids. If recovery is incomplete, 71.2% (37/52) proceed next to plasma exchange (PE). 45.5% (5/11) of paediatric neurologists use IV immunoglobulin (IVIg) in preference to PE. Following an acute attack, 55.8% (29/52) of respondents typically continue corticosteroids for ≥ 3 months; though less commonly when treating children. After an index event, 60% (31/51) usually start steroid-sparing maintenance therapy (MT); after ≥ 2 attacks 92.3% (48/52) would start MT. Repeat MOG antibody status is used by 52.9% (27/51) to help decide on MT initiation. Commonly used first line MTs in adults are azathioprine (30.8%, 16/52), mycophenolate mofetil (25.0%, 13/52) and rituximab (17.3%, 9/52). In children, IVIg is the preferred first line MT (54.5%; 6/11). Treatment response is monitored by MRI (53.8%; 28/52), optical coherence tomography (23.1%; 12/52) and MOG antibody titres (36.5%; 19/52). Regardless of monitoring results, 25.0% (13/52) would not stop MT. CONCLUSION: Current treatment of MOGAD is highly variable, indicating a need for consensus-based treatment guidelines, while awaiting definitive clinical trials.      «

INTRODUCTION: While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus on management is yet to be developed. OBJECTIVE: To survey the current global clinical practice of clinicians treating MOGAD. METHOD: Neurologists worldwide with expertise in treating MOGAD participated in an online survey (February-April 2019). RESULTS: Fifty-two responses were received (response rate 60.5%) from 86 invi...     »